Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Watson CEO Claims FTC Pressured Company To Allow Apotex To Market Generic Provigil

This article was originally published in The Pink Sheet Daily

Executive Summary

Watson CEO Paul Bisaro is fighting an FTC subpoena to testify in the commission's investigation of a reverse settlement agreement involving Cephalon's Provigil.

You may also be interested in...



Watson CEO Bisaro Ordered To Comply With FTC Subpoena

Bisaro must testify about a settlement agreement to delay marketing generic Provigil, a federal judge says; decision follows a magistrate judge's recommendation.

Watson CEO Bisaro Ordered To Comply With FTC Subpoena

Bisaro must testify about a settlement agreement to delay marketing generic Provigil, a federal judge says; decision follows a magistrate judge's recommendation.

Watson Gets To Investigate FTC Communications With FDA After Discovery Ruling

A federal judge says the facts show "the strong possibility" that FTC tried to broker a deal between Watson and Apotex requiring Watson to give up its marketing exclusivity for generic Provigil.

Related Content

Topics

UsernamePublicRestriction

Register

ID1131516

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel